193 related articles for article (PubMed ID: 33914237)
1. Papaverine, a Phosphodiesterase 10A Inhibitor, Ameliorates Quinolinic Acid-Induced Synaptotoxicity in Human Cortical Neurons.
Bhat A; Tan V; Heng B; Chow S; Basappa S; Essa MM; Chidambaram SB; Guillemin GJ
Neurotox Res; 2021 Aug; 39(4):1238-1250. PubMed ID: 33914237
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast, a cAMP-Specific Phosphodiesterase-4 Inhibitor, Reduces Oxidative Stress and Improves Synapse Functions in Human Cortical Neurons Exposed to the Excitotoxin Quinolinic Acid.
Bhat A; Tan V; Heng B; Lovejoy DB; Sakharkar MK; Essa MM; Chidambaram SB; Guillemin GJ
ACS Chem Neurosci; 2020 Dec; 11(24):4405-4415. PubMed ID: 33261317
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
Hebb AL; Robertson HA; Denovan-Wright EM
Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
5. The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson's disease mouse models.
Lee YY; Park JS; Leem YH; Park JE; Kim DY; Choi YH; Park EM; Kang JL; Kim HS
J Neuroinflammation; 2019 Dec; 16(1):246. PubMed ID: 31791357
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation.
Threlfell S; Sammut S; Menniti FS; Schmidt CJ; West AR
J Pharmacol Exp Ther; 2009 Mar; 328(3):785-95. PubMed ID: 19056933
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions.
Mango D; Bonito-Oliva A; Ledonne A; Nisticò R; Castelli V; Giorgi M; Sancesario G; Fisone G; Berretta N; Mercuri NB
Neuropharmacology; 2014 Jan; 76 Pt A():127-36. PubMed ID: 23973317
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.
Giampà C; Patassini S; Borreca A; Laurenti D; Marullo F; Bernardi G; Menniti FS; Fusco FR
Neurobiol Dis; 2009 Jun; 34(3):450-6. PubMed ID: 19281846
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 10A in the rat pineal gland: localization, daily and seasonal regulation of expression and influence on signal transduction.
Spiwoks-Becker I; Wolloscheck T; Rickes O; Kelleher DK; Rohleder N; Weyer V; Spessert R
Neuroendocrinology; 2011; 94(2):113-23. PubMed ID: 21474921
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.
Weber M; Breier M; Ko D; Thangaraj N; Marzan DE; Swerdlow NR
Psychopharmacology (Berl); 2009 May; 203(4):723-35. PubMed ID: 19066855
[TBL] [Abstract][Full Text] [Related]
13. An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders.
Sharma B; Bhattacherjee D; Zyryanov GV; Purohit R
J Biomol Struct Dyn; 2023 Nov; 41(19):9424-9436. PubMed ID: 36336960
[TBL] [Abstract][Full Text] [Related]
14. Papaverine ameliorates prenatal alcohol-induced experimental attention deficit hyperactivity disorder by regulating neuronal function, inflammation, and oxidative stress.
Sharma N; Dhiman N; Golani LK; Sharma B
Int J Dev Neurosci; 2021 Feb; 81(1):71-81. PubMed ID: 33175424
[TBL] [Abstract][Full Text] [Related]
15. The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.
Hsu YT; Liao G; Bi X; Oka T; Tamura S; Baudry M
Neuropharmacology; 2011 Dec; 61(8):1275-81. PubMed ID: 21816164
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of neurobehavioural abnormalities by papaverine in prenatal valproic acid rat model of ASD.
Luhach K; Kulkarni GT; Singh VP; Sharma B
Eur J Pharmacol; 2021 Jan; 890():173663. PubMed ID: 33127361
[TBL] [Abstract][Full Text] [Related]
19. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective Effect of Myxobacterial Extracts on Quinolinic Acid-Induced Toxicity in Primary Human Neurons.
Dehhaghi M; Tan V; Heng B; Braidy N; Mohammadipanah F; Guillemin GJ
Neurotox Res; 2019 Feb; 35(2):281-290. PubMed ID: 30267267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
